Lab
Microphase Clinical Laboratory
Microphase Clinical Laboratory was paid $483K by Medicaid between Jan 2018 and Nov 2024, across 18 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 30% of everything it billed.
33Billing provider infoMICROPHASE CLINICAL LABORATORY
HUNTSVILLE, AL 35803
HUNTSVILLE, AL 35803
33aNPI1619039047assigned 12/14/2006
33bProvider typeClinical Medical Laboratory
28Total paid$483K
24GClaims26,855
24DCodes billed18
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Alabama
Rank by total paid#25 of 61
Median peer was paid$46K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,527 | $31K | |
| 2019 | 3,774 | $46K | |
| 2020 | 4,460 | $58K | |
| 2021 | 6,295 | $89K | |
| 2022 | 6,563 | $78K | |
| 2023 | 1,531 | $86K | |
| 2024incomplete | 1,705 | $94K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 30% | 746 | 699 | $146K |
| 87184 | 20% | 2,155 | 1,752 | $97K | |
| 87070 | 15% | 7,512 | 7,119 | $70K | |
| 87077 | 14% | 7,794 | 7,130 | $67K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4.8% | 1,180 | 1,041 | $23K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.5% | 898 | 790 | $22K |
| 87075 | 2.9% | 1,678 | 1,599 | $14K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.7% | 253 | 222 | $13K |
| 87147 | 1.7% | 1,437 | 1,353 | $8K | |
| 87205 | <1% | 1,033 | 978 | $5K | |
| 87071 | <1% | 696 | 666 | $4K | |
| 87073 | <1% | 660 | 628 | $4K |
6 more codes
| 87088 | <1% | 209 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 231 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 40 | $2K |
| 87185 | <1% | 256 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 38 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 39 | $990.70 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOODY, WALTER (PRESIDENT)